Pulmonary Cell News Volume 3.45 | Nov 20 2014

An Analysis of Glucocorticoid Receptor-Mediated Gene Expression in BEAS-2B Human Airway Epithelial Cells Identifies Distinct, Ligand-Directed, Transcription Profiles with Implications for Asthma Therapeutics
A pharmacodynamics investigation of glucocorticoid receptor-mediated gene transactivation in BEAS-2B human airway epithelial cells was performed using a glucocorticoid response element luciferase reporter coupled with an analysis of glucocorticoid-inducible genes encoding proteins with anti-inflammatory and adverse-effect potential. [Br J Pharmacol] Abstract

Senescent Bronchial Fibroblasts Induced to Senescence by Cr(VI) Promote Epithelial-Mesenchymal Transition when Co-Cultured with Bronchial Epithelial Cells in the Presence of Cr(VI)
To study the evolutionary dynamics generated by the interaction between human bronchial epithelial cells and senescent bronchial fibroblasts, non-tumorigenic human bronchial epithelial BEAS-2B cells were co-cultured with Cr(VI)-induced senescent human bronchial fibroblasts for four weeks. [Mutagenesis] Abstract

Protective Effects of Sesaminol on BEAS-2B Cells Impaired by Cigarette Smoke Extract
Researchers show that sesaminol significantly improved BEAS-2B cell viability, reduced the production of reactive oxygen species and lactate dehydrogenase of cells, inhibited cell apoptosis and increased catalase and superoxide dismutase activities in cigarette smoke extract-treated cells. [Cell Biochem Biophys] Abstract

LUNG CANCER

Endogenous Lung Surfactant Inspired pH Responsive Nanovesicle Aerosols: Pulmonary Compatible and Site-Specific Drug Delivery in Lung Metastases
Researchers developed lung surfactant mimetic and pH responsive lipid nanovesicles for aerosol delivery of paclitaxel in metastatic lung cancer. 100-200 nm sized nanovesicles showed improved fusogenicity and cytosolic drug release, specifically with cancer cells. [Sci Rep] Full Article

Connexin 31.1 Degradation Requires the Clathrin-Mediated Autophagy in NSCLC Cell H1299
Connexin 31.1 (Cx31.1) was suggested to be degraded through both ubiquitin-proteasome system (UPS) and autophagy. Blockage of UPS with MG-132 increased Cx31.1 level, but could not inhibit the degradation of Cx31.1 completely. In H1299 cells stably expressing Cx31.1, Cx31.1 reduced when autophagy was induced through starvation or Brefeldin A treatment. [J Cell Mol Med] Abstract

Promoter Methylation-Mediated Silencing of β-Catenin Enhances Invasiveness of Non-Small Cell Lung Cancer and Predicts Adverse Prognosis
Researchers previously reported that the promoter of β-catenin was hypermethylated in two non-small cell lung cancer (NSCLC) cell lines. In the current study, they expanded their analysis for the methylation status of β-catenin promoter region and its protein expression in seven NSCLC cell lines and a series of 143 cases of primary human lung cancer with adjacent non-neoplastic tissues. [PLoS One] Full Article

Knockdown of PSF1 Expression Inhibits Cell Proliferation in Lung Cancer Cells In Vitro
Scientists showed that partner of sld five 1 (PSF1) was overexpressed in lung cancer samples compared to adjacent non-tumor samples. To achieve better insights of PSF1 functions in lung cancer cells, they used PSF1-specific small interfering RNA successfully inhibit the expression of PSF1 in messenger RNA and protein levels. [Tumor Biol] Abstract

Effects of VBMDMP on the Reversal of Cisplatin Resistance in Human Lung Cancer A549/DDP Cells
Scientists systematically observed the inhibitory effect of recombinant VBMDMP (rVBMDMP) on lung cancer cell growth and analyzed a possible mechanism to provide a theoretical basis for the development of new antitumor protein drugs. [Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

BIND Therapeutics Presents Positive Phase II Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-Small Cell Lung Cancer
BIND Therapeutics, Inc. presented positive results from its ongoing Phase II study of BIND-014 in non-small cell lung cancer, demonstrating it has met the primary objective in the once every three weeks arm as measured by overall response rate. [Press release from BIND Therapeutics, Inc. discussing research presented at the 26^th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, Barcelona] Press Release

Epic Sciences to Present Data on a Combination CTC and cfDNA Assay for Molecular Targets of Non-Small Cell Lung Cancer Therapies
Epic Sciences presented data describing the detection of clinically actionable non-small cell lung cancer biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood. [Press release from Epic Sciences discussing research presented at the 26^th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, Barcelona] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Polaris Group Announces Treatment of First Patient in Phase I Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma
Polaris Group announced that the first patient has been dosed in its Phase I trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung carcinoma. [Polaris Group (PR Newswire Association LLC)] Press Release

OncoTherapy Network Highlights National Lung Cancer Awareness Month
UBM Medica US announced that OncoTherapy Network, an online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discussed some of the latest research on lung cancer treatment. [UBM Medica US (PR Newswire Association LLC)] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

NEW Associate Professor – Physiology (University of Bergen)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Research Scientist – Cancer and Inflammatory Diseases (Qu Biologics Inc.)

Postdoc/Staff Scientist – Lung Fibroblast Biology (Cincinnati Children’s Hospital Medical Center)

PhD Students – Heart and Lung Research (Max Planck Institute for Heart and Lung Research)

Postdoctoral Research Fellow – Lung Pathophysiology (Brigham & Women’s Hospital – Harvard Medical School)

PhD Positions – Cardiovascular-Pulmonary Science (Chonbuk National University)

Postdoctoral Researcher – Metabolomics of Pulmonary Medicine (Karolinska Institute)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.